Boston Scientific, a manufacturer of medical devices, has completed the acquisition of Bard Electrophysiology, a division of C.R. Bard.
The completion of this transaction enables Boston Scientific to provide a broader portfolio of EP tools, including advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices.
According to Boston Scientific, the addition of legacy Bard Electrophysiology’s strong portfolio, including catheter and recording device technologies, almost doubles the size of the Boston Scientific Electrophysiology business.
Boston Scientific Electrophysiology general manager Pete Sommerness noted completing this transaction is an important part of our global strategy to grow and transform our EP business.
"We believe that the complementary capabilities that this transaction brings, including expertise in capital equipment sales and service, will enable us to offer more complete solutions to help electrophysiologists diagnose and treat patients with cardiac arrhythmias," Sommerness added.
Boston Scientific also anticipates the additional capabilities brought by the acquisition, including extended reach in strategic global markets, will help speed up the launches of key EP technologies such as the recently approved IntellaTip MiFi XP ablation catheter and Rhythmia mapping system.